Phencylidine
Phencyclidine or phenylcyclohexyl piperidine, also known as angel dust among other names, is a drug used for its mind-altering effects. PCP may cause hallucinations, distorted perceptions of sounds, and violent behavior. As a recreational drug, it is typically smoked, but may be taken by mouth, snorted, or injected.
Cluster Number:
Wiki Number: PW165
Diagnosis: Phencyclidine-PCP Related Disorders
US Patients: 2017-3% used sometime in their lives; 36% moved on into schizophrenia.
World Patients:
Sex Ratio:
Age Onset:
Brain Area: Inhibits hyppocampus, cerebellum with prolonged use leading to memory loss; acts like dopamine in its receptors
Symptoms: Drug “angel-dust” for mind-altering, hallucinations, muted sounds, violent behavior; may have adverse effects or suicide.
Progression: Unpredictable brain-altering in the short term; long-term brain damage often occurred. Resembles a schizophrenic episode.
Causes: used recreationally
Medications: benzodiazopenes for agitation and seizures; antipsychotics
Therapies: None listed.
Youtube Video:
High-resoluton targeted stimulant and phencyclidine (PCP)
Amazon or Library Book: The Truth About PCP
Click the book to link or order from Amazon.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosisÂ
Clicking each title opens the
PubMed article’s summary-abstract.
- Long-term adaptation of prefrontal circuits in a mouse model of NMDAR hypofunctionby Marion Ponserre on April 30, 2024
Pharmacological approaches to induce N-methyl-D-aspartate receptor (NMDAR) hypofunction have been intensively used to understand the aetiology and pathophysiology of schizophrenia. Yet, the precise cellular and molecular mechanisms that relate to brain network dysfunction remain largely unknown. Here, we used a set of complementary approaches to assess the functional network abnormalities present in male mice that underwent a 7-day subchronic phencyclidine (PCP 10mg/kg, subcutaneously, once...
- 3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an (18)F-FDG PET/CT Case Reportby Maria Pepe on April 27, 2024
New Psychoactive Substances (NPS) are modifying the drug scenario worldwide and have become a public health concern because of their toxicological profiles and their harmful physical/psychological effects. 3-Methoxy-Phencyclidine (3-MeO-PCP), a non-competitive antagonist of glutamate N-methyl-D-aspartate (NMDA) receptors, belongs to the phencyclidine-like subfamily of arylcyclohexylamines and has gained attention for its toxic, sometimes fatal, effects. Despite several cases of intoxication and...
- Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogensby Syed Minhaj Rahman on April 18, 2024
Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes (cannabis, MDMA, ecstasy, 3,4-methylenedioxymethamphetamine, psychedelics, hallucinogens, peyote,...
- Novel α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) potentiator LT-102: A promising therapeutic agent for treating cognitive impairment associated with schizophreniaby Xueyu Qi on April 14, 2024
CONCLUSION: We conclude that LT-102 ameliorates cognitive impairments in a phencyclidine-induced model of schizophrenia by enhancing synaptic function, which could make it a potential therapeutic candidate for CIAS.